The National Institute for Health and Care Excellence (NICE) has recommended against approving donanemab for use on the NHS in the UK, despite the Medicines and Healthcare products Regulatory Agency (MHRA) approving it as a new treatment for early-stage Alzheimer’s patients. NICE cited the high costs of treatment and the limited benefits it provides to patients as reasons for their decision. Although donanemab has shown to slow cognitive decline in trials, the health risks associated with the treatment, including brain swelling and bleeding, were also noted. The drug will now only be available for patients wishing to pay privately, with costs estimated at £25,000 to £60,000 per year.
Source link
NHS Will Not Fund Donanemab For Alzheimer’s
